Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Thybo
Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy
Onkourologiya
Oncology
Radiology
Urology
Nuclear Medicine
Nephrology
Imaging
Surgery
Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Clinical Cancer Research
Cancer Research
Oncology
Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab
Journal of Cancer Therapy
Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
